Perrigo Company plc filings document a consumer health issuer organized under Irish law, with disclosures covering operating results, non-GAAP measures, segment reporting, capital structure, governance, and material corporate events. Recent 8-K filings report quarterly earnings from continuing operations, the company's transition to product-category segments, and the completed sale of its Dermacosmetics branded business.
The filing record also covers Perrigo's ordinary shares, senior notes, revolving credit facility, and term loan arrangements, including amendments to credit agreements. Proxy and annual meeting materials document board matters, shareholder voting results, executive compensation, and the shareholder-approved 2026 Long-Term Incentive Plan.
Perrigo Company plc (PRGO) – Form 4 insider filing: Executive Vice President & President of CSCI, Roberto Khoury, reported two transactions dated 8 July 2025.
- Disposition: Khoury disposed of 5,205 ordinary shares (Table I, coded “D”). No price information was supplied in the excerpt.
- Acquisition (equity award): He received 2,211 Restricted Stock Units (RSUs) (Table II, coded “A”). Each RSU converts to one ordinary share and vests in three equal annual instalments beginning 8 July 2026.
Following the transactions, Khoury directly owns the newly granted 2,211 RSUs; the filing does not disclose his remaining ownership of ordinary shares beyond the figures above. The activity is routine executive equity compensation combined with a modest share sale, providing limited insight into fundamental performance but useful for monitoring insider sentiment and potential dilution.